Parenteral interferon-alpha treatment of psoriasis.
12 patients suffering from psoriasis were given recombinant interferon (IFN)-alpha-2c at a daily dosage of 2.5 X 10(6) or 5 X 10(6) IU for up to 4 weeks by the intramuscular route. One patient showed complete regression and remained free of lesions after 12 months of follow-up. Three patients were judged as partial remission with stop of scale formation and flattening of skin lesions. No beneficial effect was seen in 8 patients. Side effects due to IFN-alpha application, such as fever, headache, malaise, and chills disappeared with subsequent treatments. Our findings suggest a possible positive effect of IFN-alpha in psoriasis.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007370:Interferon Type I; D011994:Recombinant Proteins